Company intelligence / Profile preview
Indupro Soluciones
Seattle, Washington, United Statesinduprotx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
InduPro has raised $85 million in Series A funding to advance its first clinical product candidate targeting cancer tissue using proximity-based co-targeting. The company’s programs are currently preclinical with an IND filing anticipated in late 2025. No clinical results have been reported yet.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Bispecific monoclonal antibodyAntibody-drug conjugateMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
None publicly disclosed.
Beyond the preview
Go deeper on Indupro Soluciones.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Indupro Soluciones.